我要投票 朗迪Reneed在补钙行业中的票数:365
· 外 推 电 报 ·
2025-04-26 16:31:20 星期六

【朗迪Reneed是哪个国家的品牌?】

朗迪Reneed是什么牌子?「朗迪Reneed」是 北京振东康远制药有限公司 旗下著名品牌。该品牌发源于北京市,由创始人李昆在2003-11-07期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力朗迪Reneed品牌出海!通过在本页面挂载朗迪Reneed品牌的产品链接和联系方式,可以提高朗迪Reneed产品曝光!跨境电商爆单神器,目前只要100元/年哦~

钙营养补充剂品牌,主打维生素矿物质钙补充剂类药物,集研发、生产、销售于一体的集团化现代综合制药企业


北京振东康远制药有限公司始建于2003年10月,是国内较大的具有自主品牌的维生素矿物质钙补充剂类药物生产企业,是一家集研发、生产、销售于一体的集团化现代综合制药公司,是中国补钙药物的佼佼者和先锋。公司产品遍布全国,公司“朗迪”牌碳酸钙D3片(II)和碳酸钙D3颗粒已成为中国钙补充剂类药品市场的主流。公司2015年与上市公司振东集团山西振东制药股份有限公司强强联合,完成重大重组,实现了跨跃式发展。

公司于2009年进入中国钙制剂市场,旗下现有7家直属或控股的制药公司、2家直属药物研发公司及多家医药贸易公司,在30多个城市设立了办事机构,有数千家合作伙伴,累计总投资超过10亿元,全国有数千名员工为康远工作。

公司位于北京市昌平区西部约15公里的北京市昌平区流村工业园内,隶属中关村科技园昌平园。该厂区自2012年开始建造,总投资近亿元,按照新版欧盟GMP标准及中国GMP标准进行规划、设计和建设施工,配有国际前沿的制粒、干燥、混合、压片、包装等片剂、硬胶囊剂、颗粒剂生产线及软胶囊剂生产线,该项目已于2014年通过了BFDA组织的GMP认证,并获得片剂、硬胶囊剂、颗粒剂、软胶囊剂GMP证书。项目年生产能力近百亿片(粒、袋)。该项目的建成使康远制药一跃成为国内维生素矿物质钙补充剂类药物较大生产企业。

公司发展过程中始终以“构建国人健康骨骼”为已任,以“树民族工业品牌,为中国制药争光”为使命,为中国钙制剂的发展做出了较大的贡献,大大改善了亿万国人的生活质量。康远人负有共同的使命,遵循一致的价值观,始终秉承“济世安康、立勋鸿远”宗旨来服务社会、回报社会。目前公司年营业收入达数十亿元,年上缴税金数亿元。随着公司高速发展和对未来中国经济和全球钙制剂市场发展前景充分信心,北京振东康远制药正不断加快创新、运筹帷幄、酝酿百年规划,未来的康远终将成为一家拥有精良技术和设备、管理成熟的世界制药公司。


英文翻译:Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd., a brand of calcium supplements, is a group modern comprehensive pharmaceutical enterprise integrating R & D, production and sales. It was founded in October 2003. It is a large domestic manufacturer of vitamin and mineral calcium supplements with its own brand, integrating R & D, production and sales Group modern comprehensive pharmaceutical company is the leader and pioneer of calcium supplements in China. The company's products are all over the country, and its "landi" brand calcium carbonate D3 tablets (II) and calcium carbonate D3 particles have become the mainstream of China's calcium supplements market. In 2015, the company and the listed company Zhendong Group Shanxi Zhendong Pharmaceutical Co., Ltd. jointly completed major restructuring and achieved a leap forward development. In 2009, the company entered the calcium preparation market in China. At present, it has 7 pharmaceutical companies directly under or controlled by the company, 2 pharmaceutical research and development companies directly under the company and many pharmaceutical trading companies. It has set up offices in more than 30 cities, thousands of partners, with a total investment of more than 1 billion yuan, and thousands of employees working for Kangyuan. The company is located in Liucun Industrial Park, Changping District, Beijing, about 15km away from the west of Changping District, Beijing. The plant has been constructed since 2012, with a total investment of nearly 100 million yuan. It is planned, designed and constructed in accordance with the new version of EU GMP standard and China GMP standard. It is equipped with internationally cutting-edge tablet, hard capsule, granule production line and soft capsule production line. The project has passed the GMP certification organized by bfda in 2014, and has obtained tablet GMP certificate of hard capsule, granule and soft capsule. The annual production capacity of the project is nearly 10 billion pieces (grain and bag). With the completion of the project, Kangyuan pharmaceutical has become a large domestic manufacturer of vitamin, mineral and calcium supplements. In the development process of the company, we always take "building healthy skeleton of Chinese people" as our responsibility, take "building national industrial brand, winning honor for Chinese pharmaceutical" as our mission, and have made great contribution to the development of Chinese calcium preparation, greatly improving the quality of life of hundreds of millions of Chinese people. Kangyuan people have a common mission, follow the same values, and always adhere to the tenet of "helping the world and health, and making contributions to Hongyuan" to serve and repay the society. At present, the company's annual operating revenue is billions of yuan, and the annual tax payment is hundreds of millions of yuan. With the rapid development of the company and full confidence in the future development of China's economy and the global calcium preparation market, Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd. is constantly accelerating innovation, strategizing and brewing a hundred year plan. In the future, Kangyuan will eventually become a world pharmaceutical company with excellent technology and equipment and well managed.

本文链接: https://www.waitui.com/brand/52bc17e3b.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

多家银行发公告警示黄金投资风险,专家:信用卡炒金涉嫌违规

金价高位运行,让黄金投资持续升温。一些人贷款或用信用卡套现买黄金,还在社交媒体分享所谓的“攻略”。多家银行发出公告警示投资风险,并表示严控信用卡“炒金”。专家表示,近期黄金大幅波动,加杠杆追涨黄金,存在巨大的资金风险。此外,专家提醒,我国对贷款和信用卡资金的用途有明确要求,相关资金不得用于黄金投资等领域。(央视网)

32分钟前

高盛:3月初以来外国投资者已抛售价值630亿美元的美国股票

随着美国企业业绩前景受到关税政策的影响,资本市场上它们的股票也大量遭到抛售。据美国有线电视新闻网24日报道,早在美国政府刚开始威胁要推出关税政策时,许多投资者就已经开始抛售其手中持有的美国公司股票。报道称,今年第一季度,仅包括 摩根大通首席执行官杰米·戴蒙 和“元”公司创始人扎克伯格等在内的10名美国富豪,就抛售了总价值达39亿美元的美股。另据美国彭博新闻社25日报道,美国高盛集团称,自3月初以来,外国投资者已经抛售了价值630亿美元的美国股票。(财联社)

32分钟前

我国首台套商品化国产串列加速器研制成功

据中国原子能科学研究院报道,近日,中国原子能科学研究院为哈尔滨工程大学研制的串列加速器系统通过验收。这是国内首台套商品化串列加速器,标志着我国在串列加速器高端仪器设备制造领域取得重大突破,实现串列加速器的完全自主可控。(财联社)

32分钟前

保时捷中国研发中心落户上海虹桥国际中央商务区

保时捷近日于2025上海国际车展正式宣布,其位于虹桥国际中央商务区嘉定片区的中国研发中心已完成战略性架构升级,全新投建的上海办公新址计划于今年下半年正式投入运营。

32分钟前

教育部举办人工智能校长局长专题培训班

教育部举办人工智能校长局长专题培训班。教育部党组书记、部长怀进鹏强调,要优化知识体系,提升师生素养技能,加快建设人工智能课程体系、推进课程教材建设,全面提升教师的智能素养和育人本领。要深化平台应用,赋能教育改革创新,建强用好国家智慧教育平台,深入实施人工智能赋能教育行动,加快智能基础设施提档升级。

32分钟前

本页详细列出关于朗迪Reneed的品牌信息,含品牌所属公司介绍,朗迪Reneed所处行业的品牌地位及优势。
咨询